Search results
Showing 31 to 45 of 159 results for metastatic breast cancer
Early and locally advanced breast cancer: diagnosis and management (NG101)
This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.
Evidence-based recommendations on pembrolizumab (Keytruda) for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer in adults.
Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)
Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy.
This guideline covers how healthcare services for breast cancer should be organised. It aims to improve care for women with breast cancer by recommending which healthcare professionals should be involved in care.
Evidence-based recommendations on olaparib (Lynparza) for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy in adults.
In development [GID-TA11513] Expected publication date: 05 March 2025
In development [GID-TA11263] Expected publication date: TBC
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)
Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive, locally recurrent or metastatic (secondary) breast cancer that has not been treated with chemotherapy or targeted HER-2 therapy before, in adults.
Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)
This guideline covers diagnosing and managing secondary cancer in people aged 18 and over when the site of the primary cancer is unknown. This includes people who have had treatment for cancer before. It aims to improve quality of life by offering advice on tests for identifying the site of the primary cancer and options for managing the person’s condition.
Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours
Advanced breast cancer: diagnosis and management (Partial update)
In development [GID-NG10430] Expected publication date: TBC
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)
Evidence-based recommendations on trastuzumab (Herceptin) for treating HER2-positive metastatic gastric cancer in adults.
Evidence-based recommendations on abemaciclib (Verzenios) with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence in adults.
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)
Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive breast cancer that is locally advanced, inflammatory, or early-stage with a high risk of recurrence, in adults.
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)
Evidence-based recommendations on pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer in adults.